Daraxonrasib: A Promising New Targeted Therapy for RAS-Mutant Cancers
For decades, cancers driven by RAS mutations were considered among the hardest cancers to treat because researchers struggled to develop drugs that could effectively target the RAS protein.¹ Today, that is beginning to change with the development of daraxonrasib, an investigational targeted therapy designed to inhibit active RAS proteins across multiple RAS mutations.¹ Recent clinical studies have produced encouraging results, particularly for people with advanced pancreatic cancer, offering new hope in an area where treatment options have long been limited.²
In this blog, we explain what daraxonrasib is, how it works, and why it represents an exciting advance in precision oncology.
What Are RAS Mutations?
The RAS family of genes, including KRAS, NRAS, and HRAS, helps control how cells grow, divide, and survive.¹ When these genes become mutated, they can remain permanently switched "on," causing uncontrolled cell growth that can lead to cancer.¹ RAS mutations occur in approximately one-quarter of all cancers and are especially common in pancreatic, colorectal, and lung cancers.¹ In pancreatic ductal adenocarcinoma (PDAC), more than 90% of tumors contain an activating RAS mutation, making the RAS pathway a major driver of disease.²
What Is Daraxonrasib?
Daraxonrasib is an oral investigational RAS(ON) multi-selective inhibitor that targets the active, GTP-bound form of RAS proteins.² Unlike earlier drugs that focused on only one KRAS mutation, daraxonrasib was designed to inhibit multiple mutant forms of RAS and may also inhibit active wild-type RAS involved in cancer signaling.² This broader activity has generated significant interest because many different cancers are driven by a variety of RAS mutations.³
How Does Daraxonrasib Work?
RAS proteins normally act like molecular switches that turn cell growth signals on and off.¹ Cancer-causing RAS mutations keep this switch locked in the "on" position, allowing cancer cells to continue growing.¹ Daraxonrasib binds to the active form of RAS and blocks its ability to send growth signals inside the cancer cell.² By interrupting this signaling pathway, the drug may slow tumor growth and, in some patients, shrink tumors.¹
Encouraging Results in Pancreatic Cancer
One of the most exciting developments has been the Phase III RASolute 302 clinical trial in patients with previously treated metastatic pancreatic cancer.² The trial enrolled approximately 500 patients from North America, Europe, and Asia who had previously received treatment for metastatic pancreatic ductal adenocarcinoma.³ Patients receiving daraxonrasib experienced significantly longer progression-free survival and overall survival compared with investigator's choice chemotherapy.² Median overall survival was 13.2 months with daraxonrasib compared with 6.7 months with chemotherapy, representing nearly a doubling of survival time.² The study also demonstrated a favorable safety profile, with fewer severe side effects than standard chemotherapy.² These findings were presented during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and were simultaneously published in the New England Journal of Medicine.²
Why Are These Results So Important?
Pancreatic cancer remains one of the most difficult cancers to treat, and effective second-line treatment options have been limited.² Experts have described the RASolute 302 findings as potentially practice-changing because they demonstrate that targeting RAS can significantly improve outcomes for patients with metastatic pancreatic cancer.³ Importantly, daraxonrasib showed activity regardless of the specific KRAS mutation subtype, highlighting the potential advantage of a multi-selective RAS inhibitor.³
Researchers believe this approach could eventually benefit patients with other RAS-driven cancers as well, although additional clinical studies are still underway.²
Could Daraxonrasib Help Other Types of Cancer?
Although the strongest evidence currently comes from pancreatic cancer, RAS mutations occur in many other cancers, including lung and colorectal cancers.¹ Because daraxonrasib targets multiple RAS variants, researchers are actively studying whether its benefits can extend beyond pancreatic cancer.²
Ongoing clinical trials will help determine which patients are most likely to benefit and how the drug may be combined with other targeted therapies or immunotherapy in the future.²
Why Molecular Testing Matters
The development of daraxonrasib highlights the growing importance of comprehensive genomic testing in cancer care. Without molecular testing, many patients may never learn whether their tumor carries a RAS mutation that could make them eligible for targeted therapies or clinical trials. As precision oncology continues to evolve, identifying the specific genetic drivers of a cancer is becoming an essential step in building a personalized treatment plan.
How Navexio Helps Patients Navigate Precision Oncology
The rapid pace of cancer research makes it difficult for patients and families to keep up with emerging therapies like daraxonrasib. At Navexio, we help patients understand their genomic testing results and identify biomarkers that may open the door to targeted therapies or clinical trials.
Our Molecular & Genomic Check-Up reviews existing pathology and molecular testing to determine whether additional testing or treatment opportunities should be explored. When appropriate, we also help patients identify and navigate clinical trials investigating promising therapies such as daraxonrasib.
As precision oncology continues to transform cancer care, Navexio's mission remains the same: leave no stone unturned in helping every patient make informed, evidence-based decisions about their cancer journey.
References
O'Reilly EM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. New England Journal of Medicine. 2026;395:325-337. DOI: 10.1056/NEJMoa2605555. PubMed PMID: 42223072.
O'Reilly EM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. New England Journal of Medicine. 2026;395:325-337. DOI: 10.1056/NEJMoa2605555.
American Society of Clinical Oncology (ASCO). Multi-Selective RAS(ON) Inhibitor Nearly Doubles Survival Time in People With Metastatic Pancreatic Cancer. ASCO Press Release. May 31, 2026. Also reporting the RASolute 302 ASCO Annual Meeting presentation.